Table 3.
Association of anthropometric measures and MetS with all-cause and BC-specific mortality by molecular subtypes, Naples, Italy, 2009–2022.
| HR+ | HER 2+ | TN | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deaths from all-causes | Deaths from breast cancer | Deaths from all-causes | Deaths from breast cancer | Deaths from all-causes | Deaths from breast cancer | |||||||
| HR* (95% CI) | p** | HR* (95% CI) | p** | HR* (95% CI) | p** | HR* (95% CI) | p** | HR* (95% CI) | p** | HR* (95% CI) | p** | |
| Body mass index, kg/m2 | 0.433 | 0.087 | 0.501 | 0.183 | 0.835 | 0.855 | ||||||
| < 25 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| 25–30 | 1.10 (0.68–1.78) | 1.03 (0.53–1.99) | 0.93 (0.36–2.42) | 1.03 (0.29–3.61) | 0.76 (0.26–2.17) | 1.25 (0.38 –4.04) | ||||||
| ≥ 30 | 1.35 (0.82–2.21) | 1.78 (0.94–3.37) | 1.53 (0.64–3.68) | 2.47 (0.84–7.27) | 0.77 (0.28–2.15) | 0.88 (0.25–3.12) | ||||||
| Per 5 U | 1.21 (1.01–1.44) | 0.035 | 1.58 (1.11–1.72) | 0.004 | 1.23 (0.89–1.68) | 0.207 | 1.42 (0.94–2.16) | 0.096 | 1.11 (0.75–1.14) | 0.616 | 1.16 (0.74–1.84) | 0.519 |
| Waist circumference, cm | 0.088 | 0.052 | 0.245 | 0.087 | 0.999 | 0.993 | ||||||
| < 88 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| ≥ 88 | 1.44 (0.95–2.18) | 1.75 (0.99–3.06) | 1.59 (0.73–3.49) | 2.30 (0.89–5.99) | 1.00 (0.42–2.41) | 0.99 (0.37–2.68) | ||||||
| Per 10 U | 1.19 (1.06–1.34) | 0.004 | 1.28 (1.11–1.48) | 0.001 | 1.36 (1.04–2.77) | 0.024 | 1.62 (1.10–2.37) | 0.014 | 0.94 (0.70–1.27) | 0.696 | 0.94 (0.70–1.34) | 0.849 |
| Waist-to-hip ratio | 0.013 | 0.087 | 0.735 | 0.176 | 0.357 | 0.231 | ||||||
| ≤ 0.85 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| > 0.85 | 1.85 (1.14–2.99) | 1.67 (0.93–3.00) | 1.14 (0.53–2.44) | 1.97 (0.74–5.27) | 1.75 (0.53–5.78) | 2.27 (0.59–8.71) | ||||||
| Per 0.1 U | 1.26 (1.04–1.53) | 0.019 | 1.32 (1.03–1.68) | 0.028 | 1.42 (0.91–2.21) | 0.124 | 1.49 (0.86–2.59) | 0.154 | 1.30 (0.69–2.42) | 0.417 | 1.32 (0.67–2.61) | 0.418 |
| Metabolic syndrome (MetS) | 0.125 | 0.169 | 0.005 | 0.002 | 0.766 | 0.903 | ||||||
| No | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Yes | 1.42 (0.91–2.23) | 1.52 (0.84–2.76) | 3.45 (1.45–8.22) | 5.05 (1.80–14.20) | 1.18 (0.41–3.44) | 1.08 (0.33–3.51) | ||||||
| MetS components | 0.019 | 0.061 | 0.034 | 0.016 | 0.198 | 0.245 | ||||||
| None | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| 1–2 | 3.86 (1.37–10.84) | 3.68 (1.11–12.22) | 0.96 (0.29–3.21) | 0.55 (0.14–2.14) | 6.99 (0.84–58.08) | 6.15 (0.73–52.10) | ||||||
| ≥ 3 | 4.65 (1.59–13.57) | 4.62 (1.30–16.46) | 3.03 (0.83–11.03) | 2.94 (0.75–11.56) | 5.69 (0.59–54.77) | 4.72 (0.47–47.87) | ||||||
HR+, hormone receptor, HER2+ human epidermal growth factor receptor-2, TN triple negative.
*Cox proportional hazard ratio (HR) adjusted by terms of: age (≤ 40, 41–60, > 60), center (IRCCS G. Pascale, Policlinico Federico II), cancer stage (I–IIA, IIB, IIIA–IIIC);
**For the entire variable the p-value refers to Wald Test, for numerical variable z-Test p-value was reported.
Significant results are shown in bold.